Analysis of Mutagenic Potential of Therapeutic Vaccine Based on BPV-1 E6 Recombinant Protein Combined with Different Adjuvants
Received Date: Dec 18, 2017 / Accepted Date: Dec 25, 2017 / Published Date: Dec 30, 2017
Bovine papillomavirus is a worldwide distributed virus that affects at least 60% of Brazilian cattle herd, causing significant economic loses. Considering the great number of BPV-infected bovines, therapeutic vaccines, such those based on E6 protein, are mandatory to control the BPV-related diseases. However, the choice of the adjuvant remains challenging the vaccinology field, since adjuvants are associated with local and systemic reactions. Thus, this study analyzed the cytotoxic and mutagenic potential of BPV-1 E6 protein-based vaccine formulations using different adjuvants: aluminum hydroxide, complete and incomplete Freund’s adjuvants and two anti-oxidant saponin-rich extracts obtained from Agave sisalana-alcoholic and acid hydrolysis extract. Results of these analyzes suggest that acid hydrolysis extract from A. sisalana is an alternative and useful candidate for therapeutic vaccines, being able to reduce the mutagenic potential of antigen.
Keywords: Papillomavirus; Vaccine; E6 protein; Adjuvants; Saponin
Citation: Araldi RP, Módolo DG, de Souza JM, de Carvalho RF, dos Santos L, et al. (2017) Analysis of Mutagenic Potential of Therapeutic Vaccine Based on BPV-1 E6 Recombinant Protein Combined with Different Adjuvants. J Vet Med Health 1: 102.
Copyright: ©2017 Araldi RP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Open Access Journals
- Total views: 2809
- [From(publication date): 0-2017 - Oct 02, 2022]
- Breakdown by view type
- HTML page views: 2334
- PDF downloads: 475